PL3102189T3 - Kompozycja i sposób wspomagania snu - Google Patents

Kompozycja i sposób wspomagania snu

Info

Publication number
PL3102189T3
PL3102189T3 PL15746152T PL15746152T PL3102189T3 PL 3102189 T3 PL3102189 T3 PL 3102189T3 PL 15746152 T PL15746152 T PL 15746152T PL 15746152 T PL15746152 T PL 15746152T PL 3102189 T3 PL3102189 T3 PL 3102189T3
Authority
PL
Poland
Prior art keywords
composition
aiding sleep
aiding
sleep
Prior art date
Application number
PL15746152T
Other languages
English (en)
Inventor
Lan Bo Chen
Original Assignee
Lan Bo Chen
Sequential Medicine Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lan Bo Chen, Sequential Medicine Limited filed Critical Lan Bo Chen
Publication of PL3102189T3 publication Critical patent/PL3102189T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL15746152T 2014-02-06 2015-02-04 Kompozycja i sposób wspomagania snu PL3102189T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461936566P 2014-02-06 2014-02-06
EP15746152.6A EP3102189B1 (en) 2014-02-06 2015-02-04 Composition and method for aiding sleep
PCT/US2015/014393 WO2015120006A1 (en) 2014-02-06 2015-02-04 Composition and method for aiding sleep

Publications (1)

Publication Number Publication Date
PL3102189T3 true PL3102189T3 (pl) 2020-05-18

Family

ID=53753899

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15746152T PL3102189T3 (pl) 2014-02-06 2015-02-04 Kompozycja i sposób wspomagania snu

Country Status (21)

Country Link
US (2) US9427409B2 (pl)
EP (2) EP3632416A1 (pl)
JP (1) JP6338683B2 (pl)
KR (1) KR101774721B1 (pl)
CN (2) CN105899194B (pl)
AU (1) AU2015214285B2 (pl)
BR (1) BR112016017742A2 (pl)
CA (1) CA2934595C (pl)
DK (1) DK3102189T3 (pl)
ES (1) ES2759452T3 (pl)
HR (1) HRP20192119T8 (pl)
HU (1) HUE047654T2 (pl)
MX (2) MX373821B (pl)
MY (1) MY177906A (pl)
NZ (1) NZ720813A (pl)
PL (1) PL3102189T3 (pl)
PT (1) PT3102189T (pl)
RS (1) RS59800B1 (pl)
SG (1) SG10202004858TA (pl)
TW (1) TWI730939B (pl)
WO (1) WO2015120006A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
MY177906A (en) * 2014-02-06 2020-09-25 Sequential Medicine Ltd Composition and method for aiding sleep
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
KR20190008265A (ko) * 2016-05-06 2019-01-23 피지션즈 씰, 엘엘씨 발레리안 조성물 및 관련 방법
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
WO2020096569A1 (en) * 2018-11-06 2020-05-14 Sequential Medicine Limited Composition and method for aiding sleep
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
CN110075302A (zh) * 2019-04-19 2019-08-02 陶燃 一种治疗抑郁和失眠的组合物及其用途
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2024163966A1 (en) 2023-02-03 2024-08-08 Tris Pharma, Inc. Low sodium oxybate once nightly composition
WO2025111679A1 (pt) * 2023-11-30 2025-06-05 Prati, Donaduzzi & Cia Ltda Forma farmacêutica oral para liberação bifásica, composta por um sistema multiparticulado, processo para preparação da mesma e uso terapêutico da forma oral

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE229807T1 (de) * 1996-10-11 2003-01-15 Medichemie Ag Chronische verwendung von lorazepam und diphenhydramin
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
EP1165054A4 (en) * 1999-04-06 2005-02-09 Pharmaquest Ltd PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT DELIVERY OF METHYLPHENIDATE
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
DE60003194T2 (de) * 1999-08-26 2004-06-17 Neurocrine Biosciences, Inc., San Diego Sedativ hypnotische zusammensetzungen mit gesteuerter freisetzung und diesbezügliche verfahren
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
EP1686976A2 (en) * 2003-11-05 2006-08-09 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
KR20070087678A (ko) * 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
US20070082048A1 (en) * 2005-06-08 2007-04-12 Ronald Warner Sleep aid formulations
US20070020333A1 (en) * 2005-07-20 2007-01-25 Chin-Chih Chiang Controlled release of hypnotic agents
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
US20070190130A1 (en) * 2006-02-16 2007-08-16 Mark William A Protein hydrolysate excipients
WO2008075372A1 (en) * 2006-12-18 2008-06-26 Lupin Limited Controlled release dosage forms of zolpidem
US20080248106A1 (en) * 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
US20080254121A1 (en) 2007-04-10 2008-10-16 Iomedix Sleep International Srl Multi-layer melatonin composition
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
WO2011006012A1 (en) * 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
IT1401142B1 (it) * 2010-07-26 2013-07-12 Ambros Pharma S R L Procedimento per la preparazione di compresse a rilascio controllato comprendenti melatonina
US20130078304A1 (en) * 2011-09-28 2013-03-28 Taiwan Biotech Co., Ltd. Controlled release formulation for treating sleep disorders
CN103550775B (zh) * 2013-10-18 2017-08-25 广州共禾医药科技有限公司 一种抗失眠组合物及其应用及利用该组合物制备的多相脉冲顿释制剂及其制备方法
MY177906A (en) * 2014-02-06 2020-09-25 Sequential Medicine Ltd Composition and method for aiding sleep

Also Published As

Publication number Publication date
CN110604727A (zh) 2019-12-24
ES2759452T3 (es) 2020-05-11
EP3632416A1 (en) 2020-04-08
MX373821B (es) 2020-03-24
RS59800B1 (sr) 2020-02-28
DK3102189T3 (da) 2019-12-02
JP6338683B2 (ja) 2018-06-06
HUE047654T2 (hu) 2020-05-28
US9427409B2 (en) 2016-08-30
SG10202004858TA (en) 2020-06-29
JP2016536371A (ja) 2016-11-24
MY177906A (en) 2020-09-25
HK1222580A1 (zh) 2017-07-07
MX2016010051A (es) 2017-05-04
AU2015214285A1 (en) 2016-06-23
BR112016017742A2 (pt) 2018-06-26
EP3102189A1 (en) 2016-12-14
CN105899194A (zh) 2016-08-24
EP3102189A4 (en) 2017-07-12
TWI730939B (zh) 2021-06-21
US20160346216A1 (en) 2016-12-01
EP3102189B1 (en) 2019-09-04
US20150216811A1 (en) 2015-08-06
KR20160057479A (ko) 2016-05-23
CN105899194B (zh) 2019-10-25
CA2934595A1 (en) 2015-08-13
CA2934595C (en) 2022-06-21
MX2020003139A (es) 2020-07-28
TW201538160A (zh) 2015-10-16
HRP20192119T8 (hr) 2020-08-21
HRP20192119T1 (hr) 2020-03-06
PT3102189T (pt) 2019-12-11
AU2015214285B2 (en) 2020-07-23
WO2015120006A1 (en) 2015-08-13
KR101774721B1 (ko) 2017-09-04
NZ720813A (en) 2021-12-24

Similar Documents

Publication Publication Date Title
SG10202004858TA (en) Composition and method for aiding sleep
SI3215147T1 (sl) Nevroatenuacijske spojine norketamina in postopki
SG11201609892RA (en) Transport-container system and method
GB2524060B (en) Controller and method
SG10201405182WA (en) Method and system
AP2017009674A0 (en) Methods and compositions for treating ulcers
GB201407711D0 (en) Communnication system and related method
IL246879B (en) Preparations of Epilimod and methods of using them
GB201421814D0 (en) System and method
GB201501258D0 (en) Controller and method
SG11201608128UA (en) Polishing composition and polishing method
IL251107A0 (en) Compounds and methods
GB201514411D0 (en) Kit and method
SE1451374A1 (en) Arrangement and method for force compensation in electricalmachines
ZA201703398B (en) Pharmaceutical composition and methods
IL246831B (en) A method for the production of 1-indanols and 1-indanamines
GB201421385D0 (en) Composition and method for treating nematodes
GB201705822D0 (en) Proppant composition and method
IL246870B (en) Method for preparing 1-alkyl-3-difluoromethyl-5-fluoro-1h-pyrazole-4-carbaldehydes and 1-alkyl-3-difluoromethyl-5-fluoro-1h-pyrazole-4-carboxylates
GB201404184D0 (en) Method and system
GB201523060D0 (en) Speed-limit-compliance system and method
GB201415250D0 (en) Compound and method
GB201416082D0 (en) Method and uses
PL3134581T3 (pl) Sposób i środek do stabilizacji gruntu
GB201421947D0 (en) Elecroplating method and composition